Business Context and Reporting Period
This Form 8-K Current Report was filed by Sotera Health Company on September 3, 2025, with the earliest event reported on the same date. The filing discloses a secondary offering transaction involving the sale of existing shares by certain stockholders, not the issuance of new shares by the Company.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the specific securities transaction:
- Shares Sold: 20,000,000 shares of Common Stock.
- Price Per Share: $15.111.
- Total Transaction Value: Approximately $302.22 million (calculated as 20,000,000 shares * $15.111).
- Proceeds to Company: $0. The Company did not issue or sell any shares and will not receive any proceeds from this transaction.
Material Changes
The material change reported is the execution of an underwriting agreement with Goldman Sachs & Co. LLC on September 3, 2025, and the subsequent sale of shares by Selling Stockholders on September 5, 2025. This represents a significant change in the ownership structure of the Company's common stock, increasing the float available to the public market.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. The primary risk disclosed is the potential dilution of existing shareholders' ownership percentage due to the increased number of shares outstanding in the public market, although the Company itself receives no capital from this transaction. The validity of the shares was confirmed by legal counsel, Cleary Gottlieb Steen & Hamilton LLP.
Investor Verification Checklist
- Verify the identity of the "Selling Stockholders" listed in Schedule 2 of the Underwriting Agreement to understand the source of the shares.
- Confirm the total number of shares outstanding post-transaction to assess the impact on ownership dilution.
- Review the full Underwriting Agreement (Exhibit 1.1) for any lock-up agreements or specific conditions attached to the sale.
- Note that the Company's balance sheet and cash position remain unaffected by this transaction.